Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis

Abstract Avian-origin H5/H7 influenza has the potential to cause the next influenza pandemic. Availability of effective vaccines is an essential part of pre-pandemic preparedness. However, avian influenza surface antigens are poorly immunogenic to humans, which necessitates the use of adjuvants to a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu-Ju Lin, Yun-Jui Shih, Chang-Hsun Chen, Chi-Tai Fang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/72687914e87345858b7956993209d397
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:72687914e87345858b7956993209d397
record_format	dspace
spelling	oai:doaj.org-article:72687914e87345858b7956993209d3972021-12-02T11:41:26ZAluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis10.1038/s41598-018-29858-w2045-2322https://doaj.org/article/72687914e87345858b7956993209d3972018-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-29858-whttps://doaj.org/toc/2045-2322Abstract Avian-origin H5/H7 influenza has the potential to cause the next influenza pandemic. Availability of effective vaccines is an essential part of pre-pandemic preparedness. However, avian influenza surface antigens are poorly immunogenic to humans, which necessitates the use of adjuvants to augment the immunogenicity of pre-pandemic influenza vaccines. Aluminum salts are approved, safe, and affordable adjuvants, but their adjuvanticity for influenza vaccines remains unverified. We conducted the first meta-analysis on this issue. A total of nine randomized controlled trials (2006–2013, 22 comparisons, 2,467 participants in total) compared aluminum-adjuvanted H5N1 vaccines versus non-adjuvanted counterparts. The weighted estimate for the ratio of the seroprotection rate after a single dose of H5N1 vaccine is 0.66 (95% CI: 0.53 to 0.83) by hemagglutination-inhibition assay or 0.56 (95% CI: 0.42 to 0.74) by neutralizing titer assay. The weighted estimate for the risk ratio of pain/tenderness at injection sites is 1.85 (95% CI: 1.56 to 2.19). The quality of evidence is low to very low for seroprotection (due to indirectness and potential reporting bias) and moderate for pain/tenderness (due to potential reporting bias), respectively. The significantly lower seroprotection rate after aluminum-adjuvanted H5N1 vaccines and the significantly higher risk of pain at injection sites indicate that aluminum salts decrease immunogenicity but increase local reactogenicity of pre-pandemic H5N1 vaccines in humans.Yu-Ju LinYun-Jui ShihChang-Hsun ChenChi-Tai FangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-7 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yu-Ju Lin Yun-Jui Shih Chang-Hsun Chen Chi-Tai Fang Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis
description	Abstract Avian-origin H5/H7 influenza has the potential to cause the next influenza pandemic. Availability of effective vaccines is an essential part of pre-pandemic preparedness. However, avian influenza surface antigens are poorly immunogenic to humans, which necessitates the use of adjuvants to augment the immunogenicity of pre-pandemic influenza vaccines. Aluminum salts are approved, safe, and affordable adjuvants, but their adjuvanticity for influenza vaccines remains unverified. We conducted the first meta-analysis on this issue. A total of nine randomized controlled trials (2006–2013, 22 comparisons, 2,467 participants in total) compared aluminum-adjuvanted H5N1 vaccines versus non-adjuvanted counterparts. The weighted estimate for the ratio of the seroprotection rate after a single dose of H5N1 vaccine is 0.66 (95% CI: 0.53 to 0.83) by hemagglutination-inhibition assay or 0.56 (95% CI: 0.42 to 0.74) by neutralizing titer assay. The weighted estimate for the risk ratio of pain/tenderness at injection sites is 1.85 (95% CI: 1.56 to 2.19). The quality of evidence is low to very low for seroprotection (due to indirectness and potential reporting bias) and moderate for pain/tenderness (due to potential reporting bias), respectively. The significantly lower seroprotection rate after aluminum-adjuvanted H5N1 vaccines and the significantly higher risk of pain at injection sites indicate that aluminum salts decrease immunogenicity but increase local reactogenicity of pre-pandemic H5N1 vaccines in humans.
format	article
author	Yu-Ju Lin Yun-Jui Shih Chang-Hsun Chen Chi-Tai Fang
author_facet	Yu-Ju Lin Yun-Jui Shih Chang-Hsun Chen Chi-Tai Fang
author_sort	Yu-Ju Lin
title	Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis
title_short	Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis
title_full	Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis
title_fullStr	Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis
title_full_unstemmed	Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis
title_sort	aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/72687914e87345858b7956993209d397
work_keys_str_mv	AT yujulin aluminumsaltsasanadjuvantforprepandemicinfluenzavaccinesametaanalysis AT yunjuishih aluminumsaltsasanadjuvantforprepandemicinfluenzavaccinesametaanalysis AT changhsunchen aluminumsaltsasanadjuvantforprepandemicinfluenzavaccinesametaanalysis AT chitaifang aluminumsaltsasanadjuvantforprepandemicinfluenzavaccinesametaanalysis
_version_	1718395405370130432

Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis

Ejemplares similares